Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies for serious diseases associated with dysregulated immune responses. With a market potential of nearly 1 billion dollars and positive top-line data from its Phase 2a study for IPF, GRI Bio's GRI-0621 has the potential to be a valuable treatment for autoimmune disorders and has shown promise in resolving fibrosis in patients. While there are risks associated with clinical trials and commercialization, the potential for high rewards make this stock a positive investment outlook.

Bears say

GRI Bio is facing a negative outlook due to its long development and commercialization roads for its two drugs, GRI-0621 and GRI-0803, and the high risks associated with clinical trials and commercial failures. Despite the potential for high rewards in the billion dollar market for IPF, concerns about the balance sheet/liquidity risks and the company's ability to obtain regulatory approvals and commercialize its products outweigh the potential for growth and valuation. Additionally, changing macroeconomic factors and investor sentiment towards biotech stocks may also pose risks to the company's share price. Ultimately, the potential for success is uncertain and presents significant risks for investors.

GRI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 1 analysts, GRI has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.